alny
ALNY251.150USD
-7.200-2.79%
종가 05/09, 16:00（ET）시세는 15분 지연됩니다
32.73B시가총액
손실P/E TTM
자세한 내용은 Alnylam Pharmaceuticals Inc 회사
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
회사 정보
회사 코드ALNY
회사 이름Alnylam Pharmaceuticals Inc
상장일May 28, 2004
설립일2003
CEODr. Yvonne L. Greenstreet, M.D.
직원 수2230
유형Ordinary Share
회계 연도 종료May 28
주소675 W Kendall St
도시CAMBRIDGE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02142-1168
전화16175518200
웹사이트https://www.alnylam.com/
회사 코드ALNY
상장일May 28, 2004
설립일2003
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
57.73K
-41.71%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Chief Medical Officer, Executive Vice President - Development and Medical Affairs
Chief Medical Officer, Executive Vice President - Development and Medical Affairs
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
57.73K
-41.71%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
--
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
사업별USD
이름
수익
비율
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
지역별USD
이름
수익
비율
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
사업별
지역별
사업별USD
이름
수익
비율
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
주주
업데이트 시간: Sun, Feb 9
업데이트 시간: Sun, Feb 9
주주 통계
유형
주주 통계
주주
비율
Capital World Investors
12.73%
The Vanguard Group, Inc.
9.97%
Fidelity Management & Research Company LLC
9.93%
Capital Research Global Investors
5.34%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
56.87%
주주 통계
주주
비율
Capital World Investors
12.73%
The Vanguard Group, Inc.
9.97%
Fidelity Management & Research Company LLC
9.93%
Capital Research Global Investors
5.34%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
56.87%
유형
주주
비율
Investment Advisor
55.81%
Investment Advisor/Hedge Fund
31.92%
Corporation
3.44%
Hedge Fund
2.57%
Sovereign Wealth Fund
1.97%
Pension Fund
1.42%
Bank and Trust
1.19%
Research Firm
1.15%
Individual Investor
0.39%
Other
0.15%
기관 주식 보유
업데이트 시간: Sun, Jan 19
업데이트 시간: Sun, Jan 19
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
1268
131.09M
100.54%
-4.40M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Wellington Management Company, LLP
4.20M
3.23%
-756.72K
-15.28%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
Dodge & Cox
3.54M
2.72%
-82.27K
-2.27%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Fri, May 2
업데이트 시간: Fri, May 2
이름
비율
Tema Neuroscience and Mental Health ETF
4.8%
VanEck Biotech ETF
4.19%
Global X Genomics & Biotechnology ETF
4.07%
Invesco Nasdaq Biotechnology ETF
3.67%
ProShares Ultra Nasdaq Biotechnology
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.23%
American Century Focused Dynamic Growth ETF
3.23%
iShares Biotechnology ETF
3.11%
Franklin Genomic Advancements ETF
2.56%
SPDR S&P Biotech ETF
2.5%
더 보기
Tema Neuroscience and Mental Health ETF
비율4.8%
VanEck Biotech ETF
비율4.19%
Global X Genomics & Biotechnology ETF
비율4.07%
Invesco Nasdaq Biotechnology ETF
비율3.67%
ProShares Ultra Nasdaq Biotechnology
비율3.49%
First Trust NYSE Arca Biotechnology Index Fund
비율3.23%
American Century Focused Dynamic Growth ETF
비율3.23%
iShares Biotechnology ETF
비율3.11%
Franklin Genomic Advancements ETF
비율2.56%
SPDR S&P Biotech ETF
비율2.5%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음